Blocking CB1 Receptors in a Specific Brain Stress Region Prevented the Misery of Opioid Withdrawal in Rats
Blocking CB1 cannabinoid receptors in the bed nucleus of the stria terminalis (BNST), a brain region involved in stress and anxiety, prevented opioid withdrawal-induced place aversion in rats.
Quick Facts
What This Study Found
The bed nucleus of the stria terminalis (BNST) is part of the extended amygdala, a brain circuit involved in addiction, anxiety, and stress. Researchers investigated whether cannabinoid receptor modulation in this region could affect the aversive experience of opioid withdrawal.
In Experiment 1, infusing the CB1 antagonist AM251 directly into the BNST prevented naloxone-precipitated morphine withdrawal from producing conditioned place aversion (a measure of the unpleasant experience of withdrawal). This means blocking CB1 in the BNST eliminated the negative emotional component of opioid withdrawal.
In Experiment 2, infusing the MAGL inhibitor MJN110 (which boosts 2-AG) into the BNST did NOT prevent withdrawal aversion, unlike previous findings with MJN110 in other brain regions. This suggests different brain areas use different endocannabinoid mechanisms to process withdrawal distress.
Key Numbers
AM251 in BNST: prevented withdrawal-induced place aversion. MJN110 in BNST: did not prevent aversion (unlike in other brain regions). Previous work showed AM251 also worked in central amygdala and MJN110 worked in basolateral amygdala and insular cortex.
How They Did This
Rats were made morphine-dependent, then withdrawal was precipitated with naloxone. Conditioned place aversion measured the aversive experience of withdrawal. CB1 antagonist (AM251) or MAGL inhibitor (MJN110) was microinjected directly into the BNST before conditioning trials.
Why This Research Matters
The emotional distress of opioid withdrawal is a primary driver of relapse. Understanding exactly where and how the endocannabinoid system modulates withdrawal aversion could lead to targeted interventions that reduce the suffering of withdrawal without simply substituting one drug for another.
The Bigger Picture
This study maps the endocannabinoid-opioid interaction at the level of specific brain nuclei. The picture emerging is that CB1 receptor blockade reduces withdrawal distress through multiple connected brain regions (BNST, central amygdala), while 2-AG boosting works through different areas (basolateral amygdala, insular cortex). This regional specificity could inform more targeted therapeutic approaches.
What This Study Doesn't Tell Us
Animal study using precipitated withdrawal, which is more acute than natural withdrawal. The BNST microinjection approach is not feasible in humans. The study measured conditioned place aversion, not all aspects of withdrawal. The specific mechanism by which CB1 blockade in the BNST reduces withdrawal aversion is not fully explained.
Questions This Raises
- ?Why does CB1 blockade reduce withdrawal aversion in the BNST but 2-AG enhancement does not?
- ?Could systemic CB1 modulation be used to ease opioid withdrawal in clinical settings?
- ?What is the optimal endocannabinoid manipulation strategy across all withdrawal-relevant brain regions?
Trust & Context
- Key Stat:
- CB1 blockade in the BNST eliminated the emotional misery of opioid withdrawal in rats
- Evidence Grade:
- Preliminary evidence from a single animal study with region-specific brain manipulations.
- Study Age:
- Published in 2017. Preclinical research on endocannabinoid-opioid interactions.
- Original Title:
- CB₁ receptor antagonism in the bed nucleus of the stria terminalis interferes with affective opioid withdrawal in rats.
- Published In:
- Behavioral neuroscience, 131(4), 304-11 (2017)
- Authors:
- Wills, Kiri L(3), DeVuono, Marieka V(10), Limebeer, Cheryl L(11), Vemuri, Kiran, Makriyannis, Alexandros, Parker, Linda A
- Database ID:
- RTHC-01552
Evidence Hierarchy
Tests effects in animals (usually mice or rats), not humans.
What do these levels mean? →Frequently Asked Questions
Could targeting cannabinoid receptors help with opioid withdrawal?
This study and related work suggest that modulating the endocannabinoid system in specific brain regions can reduce the emotional distress of opioid withdrawal. However, this research used direct brain injection in rats, which cannot be done in humans. Systemic cannabinoid medications that affect these same pathways are a possible future direction.
Does cannabis help with opioid withdrawal?
This study did not test cannabis but showed that blocking (not activating) CB1 receptors in a specific brain region reduced withdrawal distress. The relationship between cannabis use and opioid withdrawal is complex, and this study suggests the mechanism may involve CB1 receptor dynamics that are different from simply taking cannabis.
Read More on RethinkTHC
- cannabis-dependence-physical-psychological-addiction-science
- cannabis-perception-vs-evidence-gap
- cannabis-use-disorder-test
- cross-addiction-quit-weed-start-drinking
- is-weed-addictive
- is-weed-addictive-science
- quitting-weed-and-alcohol
- rehab-for-weed-addiction-necessary
- signs-of-cannabis-use-disorder
- weed-vape-pen-addiction
Cite This Study
https://rethinkthc.com/research/RTHC-01552APA
Wills, Kiri L; DeVuono, Marieka V; Limebeer, Cheryl L; Vemuri, Kiran; Makriyannis, Alexandros; Parker, Linda A. (2017). CB₁ receptor antagonism in the bed nucleus of the stria terminalis interferes with affective opioid withdrawal in rats.. Behavioral neuroscience, 131(4), 304-11. https://doi.org/10.1037/bne0000201
MLA
Wills, Kiri L, et al. "CB₁ receptor antagonism in the bed nucleus of the stria terminalis interferes with affective opioid withdrawal in rats.." Behavioral neuroscience, 2017. https://doi.org/10.1037/bne0000201
RethinkTHC
RethinkTHC Research Database. "CB₁ receptor antagonism in the bed nucleus of the stria term..." RTHC-01552. Retrieved from https://rethinkthc.com/research/wills-2017-cb-receptor-antagonism-in
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.